Top Midday Decliners

MT Newswires Live01-13

Atara Biotherapeutics (ATRA) said Monday the US Food and Drug Administration is "unable" to approve its biologics license application for EBVALLO as a monotherapy treatment for the Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

Shares of the company slid 54% as intraday trading volume soared to over 4.07 million from a daily average of about 92,000.

Lyra Therapeutics (LYRA) said Monday its board has decided to suspend further development of LYR-210, the company's lead product candidate for the treatment of chronic rhinosinusitis.

Shares sank 47% following an increase in intraday trading volume to over 1.26 million from a daily average of about 49,000.

RBC Capital Markets said some credit card issuers may see their revenue slashed by more than half as a result of a 10% interest rate cap floated by President Donald Trump, according to a client note. Late Friday, Trump said in a social media post that he was calling for a one-year cap on credit card interest rates at 10%, beginning Tuesday next week.

Among the decliners in the financial services sector was Synchrony Financial (SYF), with shares down 9.2% and intraday trading volume jumping to over 7 million from a daily average of about 3.29 million.

Price: 6.01, Change: -7.66, Percent Change: -56.04

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603521525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603521525","market":"hk","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> (ATRA) said Monday the US Food and Drug Administration is \"unable\" to approve its biologics license application for EBVALLO as a monotherapy treatment for the Epstein-Barr virus-positive post-transplant lymphoproliferative disease.</p><p>Shares of the company slid 54% as intraday trading volume soared to over 4.07 million from a daily average of about 92,000.</p><p><a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> (LYRA) said Monday its board has decided to suspend further development of LYR-210, the company's lead product candidate for the treatment of chronic rhinosinusitis.</p><p>Shares sank 47% following an increase in intraday trading volume to over 1.26 million from a daily average of about 49,000.</p><p>RBC Capital Markets said some credit card issuers may see their revenue slashed by more than half as a result of a 10% interest rate cap floated by President Donald Trump, according to a client note. Late Friday, Trump said in a social media post that he was calling for a one-year cap on credit card interest rates at 10%, beginning Tuesday next week.</p><p>Among the decliners in the financial services sector was <a href=\"https://laohu8.com/S/SYF\">Synchrony Financial</a> (SYF), with shares down 9.2% and intraday trading volume jumping to over 7 million from a daily average of about 3.29 million.</p><p>Price: 6.01, Change: -7.66, Percent Change: -56.04</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-13 04:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> (ATRA) said Monday the US Food and Drug Administration is \"unable\" to approve its biologics license application for EBVALLO as a monotherapy treatment for the Epstein-Barr virus-positive post-transplant lymphoproliferative disease.</p><p>Shares of the company slid 54% as intraday trading volume soared to over 4.07 million from a daily average of about 92,000.</p><p><a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> (LYRA) said Monday its board has decided to suspend further development of LYR-210, the company's lead product candidate for the treatment of chronic rhinosinusitis.</p><p>Shares sank 47% following an increase in intraday trading volume to over 1.26 million from a daily average of about 49,000.</p><p>RBC Capital Markets said some credit card issuers may see their revenue slashed by more than half as a result of a 10% interest rate cap floated by President Donald Trump, according to a client note. Late Friday, Trump said in a social media post that he was calling for a one-year cap on credit card interest rates at 10%, beginning Tuesday next week.</p><p>Among the decliners in the financial services sector was <a href=\"https://laohu8.com/S/SYF\">Synchrony Financial</a> (SYF), with shares down 9.2% and intraday trading volume jumping to over 7 million from a daily average of about 3.29 million.</p><p>Price: 6.01, Change: -7.66, Percent Change: -56.04</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LYRA","symbol_name":"Lyra Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603521525","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603521525","pubTimestamp":1768249083,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Atara Biotherapeutics (ATRA) said Monday the US Food and Drug Administration is \"unable\" to approve its biologics license application for EBVALLO as a monotherapy treatment for the Epstein-Barr virus-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LYRA":"Lyra Therapeutics","SYF":"Synchrony Financial","BK4166":"消费信贷","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4561":"索罗斯持仓","LU1861217088.USD":"贝莱德金融科技A2","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","BK4139":"生物科技","LU2360107671.USD":"BGF FINTECH \"A4\" (USD) INC","BK4007":"制药","ATRA":"Atara Biotherapeutics","LU0106831901.USD":"贝莱德世界金融基金A2","LU1861220207.SGD":"Blackrock FinTech A2 SGD-H","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H"},"translate_title":"午盘跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LYRA":1,"ATRA":1,"SYF":1},"content_text":"Atara Biotherapeutics (ATRA) said Monday the US Food and Drug Administration is \"unable\" to approve its biologics license application for EBVALLO as a monotherapy treatment for the Epstein-Barr virus-positive post-transplant lymphoproliferative disease.Shares of the company slid 54% as intraday trading volume soared to over 4.07 million from a daily average of about 92,000.Lyra Therapeutics (LYRA) said Monday its board has decided to suspend further development of LYR-210, the company's lead product candidate for the treatment of chronic rhinosinusitis.Shares sank 47% following an increase in intraday trading volume to over 1.26 million from a daily average of about 49,000.RBC Capital Markets said some credit card issuers may see their revenue slashed by more than half as a result of a 10% interest rate cap floated by President Donald Trump, according to a client note. Late Friday, Trump said in a social media post that he was calling for a one-year cap on credit card interest rates at 10%, beginning Tuesday next week.Among the decliners in the financial services sector was Synchrony Financial (SYF), with shares down 9.2% and intraday trading volume jumping to over 7 million from a daily average of about 3.29 million.Price: 6.01, Change: -7.66, Percent Change: -56.04","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603521525","isCrawlerRequest":true}